U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data Guidance for Industry and Other Stakeholders
  1. Drugs

Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data Guidance for Industry and Other Stakeholders

PDF Version of this Guidance

This guidance provides information on how a person can submit a proposed draft guidance 16 relating to patient experience data for consideration by FDA. This guidance is intended to assist 17 stakeholders seeking to develop and submit such proposed draft guidance to the Agency. In 18 addition, FDA recognizes that stakeholders may have other information on patient experience 19 data that they would like to share with FDA outside of the guidance process and thus provides 20 information on other ways stakeholders can advance drug development by sharing patient 21 experience data. Section 3002(c)(5) of the 21st Century Cures Act (Cures Act) directs FDA to issue guidance on how a person seeking to develop and submit a proposed draft guidance relating to patient experience data for consideration by FDA may submit such proposed draft guidance to the Agency

Back to Top